Dr. David Spetzler joined Caris Life Sciences in August of 2009, and has held several management positions with increasing responsibilities during his tenure. He currently serves as President and Chief Scientific Officer and provides executive leadership for the company’s service lines, Caris Molecular Intelligence® and ADAPT Biotargeting System™.
Under his leadership, the R&D team is focused on the development of clinical assays to aid in the creation of precision medicine strategies for individual cancer patients, as well as noninvasive technologies to identify and predict early stage cancer. Much of work is focused on the development of the ADAPT Biotargeting System™, a groundbreaking and proprietary method of profiling macro-molecular complexes in their native form in a highly multiplexed format. The innovative technology is the result of the convergence of Caris’ deep expertise in Next-Generation Sequencing, exosome biology, bioinformatics and broad-based molecular profiling.
Prior to his position at Caris, Dr. Spetzler was a member of the research faculty at Arizona State University where he developed multiplexed nanotechnologies for single molecule detection of nucleic acid and protein targets. He also developed novel methods of using DNA to create biological computers to solve NP-complete optimization problems, and built a novel optical detection system capable of measuring single molecule protein conformational changes with microsecond time resolution. At Arizona State University Dr. Spetzler earned an MS from the School of Mathematical and Statistical Science in Computational Bioscience, a Ph.D. in Molecular Cellular Biology and an MBA. Dr. Spetzler is an adjunct faculty member of the molecular cellular biology program at Arizona State University, a scientific and commercial reviewer for SBIR/STTR grants for NSF, co-authored more than twenty patents, and has published numerous research articles.